Shares of Tharimmune, Inc. (NASDAQ:THAR – Free Report) are scheduled to reverse split on Tuesday, May 28th. The 1-15 reverse split was announced on Tuesday, May 28th. The number of shares owned by shareholders will be adjusted after the market closes on Tuesday, May 28th.
Tharimmune Stock Performance
Tharimmune stock opened at $0.33 on Friday. The stock has a fifty day moving average price of $0.39 and a 200 day moving average price of $0.87. Tharimmune has a 52 week low of $0.31 and a 52 week high of $10.87.
Tharimmune (NASDAQ:THAR – Get Free Report) last released its earnings results on Thursday, May 9th. The company reported ($0.19) EPS for the quarter.
Tharimmune Company Profile
Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).
Recommended Stories
- Five stocks we like better than Tharimmune
- Bank Stocks – Best Bank Stocks to Invest In
- What is a Short Call Butterfly Spread? Explanation with Examples
- Investing In Preferred Stock vs. Common Stock
- First Quarter Wrap-Up Reveals Retail’s Shifting Sands
- How to Calculate Stock Profit
- Williams-Sonoma Stock Forecast to Hit $500? Here’s How
Receive News & Ratings for Tharimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tharimmune and related companies with MarketBeat.com's FREE daily email newsletter.
